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Background
Botulism is a neuroparalytic illness caused by botulinum
neurotoxin (BoNT). Seven BoNT serotypes (designated as A
to G) are produced by Clostridium botulinum, a spore-forming,
obligate anaerobic bacterium. BoNT, widely considered the
most potent toxin known and a major bioweapon [1], is a
potent blocker of synaptic transmission in peripheral
cholinergic nervous system synapses, thereby causing
paralysis. Based on its exquisitely powerful neuroparalytic
activity, BoNT has gained tremendous popularity in the past
few years since becoming the ﬁrst biological toxin (BoNT
serotype A) to receive US Food and Drug Administration
approval for the treatment of human disease [2].
Biochemically, BoNTs are synthesized as single polypeptide
chains and then cleaved by bacterial proteases into a di-chain
molecule linked by a disulﬁde bond: an ;50-kDa light chain
(LC) and an ;100-kDa heavy chain (HC). Structurally, BoNTs
encompass three modules [3–6]: the N-terminal LC is a
metalloprotease, whereas the HC comprises the translocation
domain (the N-terminal segment) and the receptor-binding
domain (the C-terminal segment). The modular architecture
of the neurotoxin is clearly visible in the crystal structures of
BoNT/A [4] (Figure 1A) and BoNT/B [6]. All seven BoNT
serotypes exhibit signiﬁcant amino acid sequence
conservation [5], although all are antigenically distinct.
It is generally agreed that BoNTs exert their neurotoxic
effect by a four-step mechanism [3,7] that involves (1) binding
to high-afﬁnity receptors on peripheral nerve endings, (2)
receptor-mediated endocytosis, (3) LC translocation across
endosomal membranes into the cytosol upon exposure to
endosomal pH, and (4) proteolytic degradation of target. The
BoNT LCs are sequence-speciﬁc endopeptidases that cleave
SNARE (soluble N-ethylmaleimide-sensitive factor
attachment protein receptor) proteins. SNAREs form a
complex that mediates synaptic vesicle fusion [8–10].
Accordingly, SNARE proteolysis destabilizes or prevents full
assembly of the SNARE core complex, abrogating fusion of
synaptic vesicles with the plasma membrane, thereby aborting
neurotransmitter release [3,11]. BoNT serotypes A, E, and C
all cleave the plasma membrane–associated protein SNAP-25
(synaptosome-associated protein of 25 kDa), and serotype C
also cleaves the plasma membrane–associated SNARE
syntaxin. In contrast, BoNT/B, D, F, and G all proteolyze
synaptobrevin, a synaptic vesicle–associated membrane
protein, also known as VAMP, at unique sites [3]. The active
site region of the BoNT LCs shares structural similarity to the
Zn
2þ-metalloprotease thermolysin [4,6,12–17]. In contrast to
other Zn
2þ-proteases, the BoNTs require an extended
enzyme-substrate interface for optimal catalytic efﬁciency
[18–20]. Indeed, the X-ray structure of BoNT/A-LC in
complex with sn2 [16]—the C-terminal residues 141–204 of
BoNT/A substrate SNAP-25—revealed an extensive array of
substrate binding sites distant from the active site (exosites)
that orient the substrate onto the vicinity of the active site
and determine the target speciﬁcity [16,21].
A key step for intoxication is the translocation of
endocytosed toxin across intracellular membranes to reach
its cytosolic targets [3]. The HC likely acts as both a channel
and a transmembrane chaperone for the LC protease to
ensure a translocation-competent conformation during
transit from acidic endosomes into the cytosol [22–24]. The
details of the translocation process are largely unknown.
However, available crystal structures of BoNT/A [4] and
BoNT/B [6] holotoxins and of BoNT/A-LC in complex with
sn2 [16] provide illuminating clues about possible
mechanisms, which we consider next.
The so-called translocation domain belt is a most
intriguing structural feature in the crystal structures of both
BoNT/A [4] and BoNT/B [6]: It is a loop in a mostly extended
conformation (consisting of residues 492–545 for BoNT/A,
and 481–532 for BoNT/B) that wraps around the catalytic
domain in the structures solved at pH 7.0 and 6.0,
respectively. The active site of the LC is buried ;20 A ˚ deep in
the protein and is accessible through a negatively charged
crevice, which may be partially occluded by the belt in the
unreduced holotoxin. The belt is highlighted in magenta on
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addition, there is a second unstructured loop encompassing
residues 449–491 for BoNT/A; this segment, depicted in gold,
is partially apposed to the LC, perpendicular to the belt, and
is parallel to the long helices of the translocation domain. The
structure of the BoNT/A-LC complex with the sn2 segment
[16] is shown in Figure 1B. Figure 1C displays a superposition
of the Ca positions of the structures of the BoNT/A-LC
complex with the sn2 segment (red), the HC belt of BoNT/A
(magenta), and the HC belt of BoNT/B (lime). The belt of
BoNT/A is more distant to the catalytic Zn
2þ (distance
between M
530 and Zn
2þ is ;15 A ˚ ) than the cognate substrate
(distance between Q
197 and Zn
2þ is ;7A ˚ ). Note the
remarkable structural similarity between sn2 and the belt in
the absence of stringent sequence similarity [5,6]. This is
relevant given the low sequence similarity (24%) of the belts
among the seven BoNT serotypes and the related clostridial
toxin, tetanus [5,25].
What is the role of this belt?
Hypothesis
We propose that the belt region of the BoNT HC is a
surrogate pseudosubstrate inhibitor of the LC protease and
acts as a chaperone during translocation across the
endosomal membrane into the cytosol. The key points are: (1)
The intrinsically unstructured sn2 fragment of SNAP-25
[16,26] adopts partial secondary structural elements upon
binding to the LC in the binary complex crystal structure [16]
and occupies a similar position as the belt in the holotoxin
crystal structures of both BoNT/A [4] and BoNT/B [6]. (2) In
analogy to other ‘‘intrinsically unstructured proteins’’ (IUPs)
[27,28], the belt undergoes binding to its LC partner, thereby
functioning as a chaperone [24]. (3) The belt occupies the
exosites, the extensive enzyme surface allocated for substrate
binding, yet it does not contain the scissile bond, thus
potentially inhibiting the LC protease.
Mechanism
A number of plausible mechanisms can be envisioned. One,
protein-assisted unfolding and pseudosubstrate-assisted
refolding of the protease could be an attribute of chaperone
action. There is precedence for protease inhibitors acting as
intramolecular chaperones [29,30]. A case in point is
subtilisin, for which propeptides, located between the signal
peptide and the mature segments of the protease, function as
protease inhibitors by lodging into the substrate binding
pocket [30]. These peptides are effectively IUPs [26] because
they lack 3-D structure in isolation, yet adopt secondary
structure upon forming a complex with the cognate protease
[29–31]. They are involved in the last steps of protein folding
of the enzyme. The crystal structure at 2.0 A ˚ resolution of the
propeptide–subtilisin complex shows that the prosegment C-
terminus (Figure 2, magenta) binds in the enzyme active site
(Figure 2, cyan) in a product-like manner with Y
77 (tip of the
b-strand) in the P1 binding pocket [32,33]. POIA1 (Pleurotus
ostreatus proteinase A inhibitor 1, PDB accession code 1ITP
[34]), a mushroom peptide that acts as an intramolecular
chaperone and inhibitor to subtilisin yet has only 18%
sequence similarity to the cognate propeptide, has a similar
tertiary structure to that of the propeptide of subtilisin.
Similar mechanisms have been found for other bacterial
proteases, including metalloproteases [29]. The analogy that
emerges from the considerations described here for BoNT is
remarkable and may be the crucial event underlying the
doi:10.1371/journal.ppat.0020113.g001
Figure 1. Structures of BoNT/A Holotoxin, BoNT/A LC-sn2 Complex, and Overlay of sn2 Segment with Belt Regions of BoNT/A and BoNT/B
(A) Structure of BoNT/A. The Ca backbone of the LC (left) is represented as cyan ribbons; the purple sphere highlights the catalytic Zn
2þat the protease
active site. The HC belt segment encompassing residues 492–545 is displayed in magenta and the 449–491 region in gold. The HC is depicted in blue, in
which the helical module (middle) is the translocation domain, and the two sub-domains consisting primarily of b-strands constitute the receptor-
binding domain (right).
(B) Structure of BoNT/A-LC in complex with the sn2 segment of SNAP-25 [16]. The Ca backbone of the LC is represented as cyan ribbons and its
molecular surface in transparent grey. The sn2 segment is depicted in red and the catalytic Zn
2þ at the active site as a purple sphere.
(C) Superposition of the structures of the sn2 segment in complex with the LC/A, the HC belt of BoNT/A, and the HC belt of BoNT/B. LC removed for
display. For the superposition, the backbone atoms of the LCs were used for the best fit between the structures. sn2 segment depicted in red; overlay of
the Ca backbone of BoNT/A [4] and BoNT/B [6] belts represented as magenta and lime ribbons. Spheres represent the catalytic Zn
2þat the active site of
BoNT/A (red and magenta) and BoNT/B (lime). All images were rendered with YASARA [40].
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chaperone. However, the belt does not actually protrude into
the BoNT active site. The putative inhibitory activity of the
belt would therefore be restricted to the remote substrate
binding interfaces of the exosites.
Two, the belt as a continuous segment, residues 449–545
for BoNT/A, may undergo a concerted structural transition at
endosomal pH with profound consequences for the
translocation process [24]. It is conceivable that a pH-induced
transition of this segment may trigger the insertion of the
translocation domain into the membrane. Since the belt
embraces the LC, the belt may be a structural entity that
facilitates or coordinates the concerted partial unfolding of
the LC at the endosomal acidic pH and directs the beginning
of its translocation through the membrane.
Three, a surrogate pseudosubstrate role is plausible. There
is weak sequence similarity between the HC belt and sn2,
which extends up to residue D
195 of SNAP-25 and E
528 of the
HC belt [16,21,35]. Furthermore, the LC undergoes
autocatalytic proteolytic fragmentation [17,36], which is
prevented in the presence of a competitive inhibitory peptide
with a sequence of CRATKML [19]; this peptide closely
emulates the sequence of the SNAP-25 C-terminal fragment
released by proteolysis of SNAP-25 (residues 197–203 with
sequence QRATKML [20], in which the scissile bond is
between Q
197 and R
198). However, this non-speciﬁc
autocatalytic activity is known to occur only at high enzyme
concentrations, such as in the context of crystallization trials,
so a physiological role is questionable.
It is conceivable that combinations of these three
mechanisms act in concert to enhance translocation
efﬁciency. A relevant example is the extensively studied
bacterial a-lytic protease (a-LP) [37,38]. The native state of a-
LP is unstable and, if unfolded, exhibits a large barrier to
refold. Folding of a-LP requires the chaperone activity of its
N-terminal pro-domain, which confers strong inhibition on
the protease. a-LP initiates degradation of the pro-domain by
proteolytic cleavage of an intervening loop at the C-end of
the pro-domain, thereby releasing the a-LP from the pro-
domain and allowing folding. Cleavage of a-LP pro-domain,
therefore, enables efﬁcient folding by lowering the free
energy of the folded state and lowering the transition state
barrier between unfolded and folded states. Upon release of
the pro-domain, the kinetic barriers for unfolding
dramatically increase and the a-LP becomes highly protease
resistant. Concurrently, the folded state becomes destabilized
yet remains kinetically trapped in its native state by a large
transition state barrier. We speculate that the belt could
enable efﬁcient folding and/or unfolding akin to the a-LP
pro-domain. Once it is released inside the neuron, the
protease is kinetically trapped and resistant to degradation
by cellular proteases or autoproteolysis, thereby implying a
convergence of chaperone and surrogate substrate
mechanisms. Combined with the exquisite neurotropism of
BoNT conferred by its receptor-binding domain, and the
target speciﬁcity and optimal catalytic efﬁciency endowed on
its protease domain, the holotoxin emerges as a marvel of
protein design.
Concluding Remarks and Perspective
These hypotheses naturally lead to testable questions: Is a
beltless holotoxin toxic in vivo, e.g., in the context of a mouse
toxicity bio-assay [39]? Is the belt required for channel
formation? Is it required for LC translocation? Is the belt the
trigger for translocation or a modulator? Are there
conformational transitions upon entering the acidic
environment of the endosome? The implication is that the
belt region of BoNT/A HC must be subjected to a rigorous
structural and functional analysis to evaluate its possible role
in the translocation process, in particular with regards to a
pH-induced conformational change. Accordingly, beltless
variants of the HC, in which the belt region is eliminated or
systematically truncated, could be recombinantly expressed,
and their channel and translocation activities examined after
reconstitution in lipid bilayers [24] and in neuronal cells
[22,23] as described for the intact BoNT/A.
A surrogate pseudosubstrate role of the belt could be
probed by using synthetic peptides that mimic the amino acid
sequence of the belt, yet incorporate SNAP-25 residues
present at the toxin cleavage site as potential toxin substrates.
Conversely, one could design a synthetic holotoxin in which
the HC belt is replaced by the sn2 segment of SNAP-25
(Figure 1B), comprising a non-cleavable bond instead of the
native scissile bond. Would this chimera exhibit translocation
features comparable to those of the native holotoxin?
Are the belt regions truly IUPs, and do they contribute to
the thermodynamic stability of the LCs? To assess whether
belt peptides are true IUPs, their solution structures could be
assessed with circular dichroism and nuclear magnetic
resonance spectroscopies. To investigate the chaperone
activity of the belt, the unfolding and refolding kinetics of LC
protease could be studied in the absence and presence of
peptides that imitate the belt (Figure 1C) and compared to
those of a complex of LC/A and sn2 (Figure 1B). Answers to
these questions could substantially improve our
understanding of the most enigmatic step in the molecular
mechanism of BoNT intoxication. &
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Accession Numbers
The Protein Data Bank (PDB, http://www.rcsb.org/pdb/) accession
codes for the proteins discussed in this paper are BoNT/A (3BTA [4]),
BoNT/A-LC in complex with the sn2 segment of SNAP-25 (1XTG
[16]), BoNT/B (1EPW [6]), and subtilisin BPN’ prosegment complexed
with a mutant subtilisin BPN’ (1SPB [32,33]).
doi:10.1371/journal.ppat.0020113.g002
Figure 2. Structure of the Subtilisin–Pro-Domain Complex
The Ca backbone of subtilisin is represented as cyan ribbons and that of
the pro-domain in magenta. Note that the C-terminus of the pro-domain
is lodged in a crevice at the protease active site; the tip of the b-strand
highlights Y
77 at the active site. Image rendered using subtilisin BPN’
prosegment complexed with a mutant subtilisin BPN’ [31,32] with
YASARA [40].
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